Intervention

Ezetimibe

ClinicalTrials.gov intervention label

Clinical trials12

Recruiting1

Common conditions18

Lead sponsors shown11

Clinical trials

12 shown

Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate CancerNCT06437574 · 2024-07-16

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)NCT02642159 · 2016-03-15

Randomized Trial Comparing Colesevelam vs. EzetimibeNCT02682680 · 2016-01-11

A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)NCT01611883 · 2012-07-02

Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol TargetsNCT00908011 · 2009-06-01

Effects of Ezetimibe Add-On to Statin Therapy on Adipokine Production in Obese and Metabolic Syndrome Patients With AtherosclerosisNCT00485121 · 2007-04-01

Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering TreatmentNCT01035320 · 2006-01-01

Safety, Effectiveness, and Tolerability of Ezetimibe Combined With Statins for the Treatment of High Cholesterol in HIV Infected AdultsNCT00099684 · 2005-11-01

Effect of Simvastatin and Ezetimibe on Lipid and InflammationNCT01103648 · 2005-06-01

Ezetimibe and Simvastatin in Dyslipidemia of DiabetesNCT00157482 · 2005-01-01

Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELLNCT00079638 · 2004-04-01

Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)NCT00651014 · 2004-01-01

Common conditions

Hypercholesterolemia4 Atherosclerosis2 Dyslipidemia2 HIV Infections2 Cardiovascular Risk1 Coronary Artery Disease1 Coronary Heart Disease1 Diabetes1 Diabetes Mellitus1 Impaired Renal Function1 Inflammation1 Metabolic Syndrome1 Obesity1 Prediabetes1 Prostate Cancer1 Stroke1 Type 2 Diabetes1 Type 2 Diabetes Mellitus1

Leading sponsors

Organon and Co2 Canadian Collaborative Research Network1 Cedars-Sinai Medical Center1 Federal University of São Paulo1 Karolinska Institutet1 Kos Pharmaceuticals1 LMC Diabetes & Endocrinology Ltd.1 Mario Negri Institute for Pharmacological Research1 National Institute of Allergy and Infectious Diseases (NIAID)1 Sanofi1 University of British Columbia1

Trial status mix

COMPLETED10

RECRUITING1

TERMINATED1

Phase mix

PHASE46

NA4

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.